血管靶向药物研究进展详解演示文稿.pptVIP

* 关于恩度治疗实体瘤应用研究新进展方面的第三小部分：恩度治疗肺外实体肿瘤的应用研究。 * 在刚刚结束的ASCO会议上，除了恩度115研究的最新数据，另外一项恩度联合达卡巴嗪一线治疗黑色素瘤的随机双盲多中心研究结果同样引人注目。恩度联合达卡巴嗪能显著提高黑色素瘤患者的PFS和OS，这是恩度继肺癌之后又一突破性研究结果。 * Maint was offered but protocol doesn’t test necessity * Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma. (NC Abstract: Background: rh-endostatin (Endostar, water-soluble, rES) is an inhibitor of angiogenesis, which is effective as single agent or in combination with chemotherapy for non-small c